A prospective open-label study of aripiprazole in fragile X syndrome. - Wikidata - awgldk - TriplyDB

A prospective open-label study of aripiprazole in fragile X syndrome.

A prospective open-label study of aripiprazole in fragile X syndrome.

http://www.wikidata.org/entity/Q47293259

about

Aripiprazole for treating irritability in children & adolescents with autism: A systematic review Emerging pharmacologic treatment options for fragile X syndrome Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES Changes in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndrome Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome.Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.Prolactin serum concentrations during aripiprazole treatment in youth.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Outcome measures for clinical trials in fragile X syndrome.The challenges of clinical trials in fragile X syndrome.Development of mavoglurant and its potential for the treatment of fragile X syndrome.Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.Molecular medicine of fragile X syndrome: based on known molecular mechanisms.Public Health Literature Review of Fragile X Syndrome.Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

P2860

Q26784199-06777807-B0F5-4F00-8A37-E0E467B9E4ED Q26829152-EA56EE2A-B8B9-4645-B808-03EF980C804B Q28073540-7519ECF0-FDA4-4ED6-B8DE-16F13A59B1BB Q28394524-D37EACDC-ECCA-4F1F-99B9-E5AFC54DB7F2 Q33785978-D1BE99EE-74E7-4416-877E-B0A17264634F Q34207747-C48BB3A3-5C56-4EA0-828F-9ADDA02C8FCC Q35013074-4AA7FE5C-5518-489A-906C-11866E16D6FA Q35035766-2CB03529-1E3D-49AD-B832-2CA5DE8C30DF Q35050550-302FD189-1671-4A7E-AA58-C16BC650EDD7 Q35614072-7C8940ED-AD62-4F98-8839-A8BD92C96516 Q36147870-A11DCB7D-651D-4421-8D9D-7AD93298C17E Q36157807-6DFE3F1A-6DD8-48DE-9836-33561C8E2FCF Q36853126-56C86E4C-5F95-469A-8064-7A4C6B302714 Q37054398-1411D761-5B5F-434C-B7E3-3EDF90A185EA Q37199656-E52B3622-0A30-41FC-B5E3-15359F2D20BB Q37598441-2B25053F-F046-43E2-BD80-97D14B02829A Q38164021-448CE672-9560-4A6F-A127-0BA12775D1A1 Q38621496-01C25B86-199A-4F44-89AA-EEA5FC5D5575 Q38627691-706F6228-234A-467A-A02C-3EE33FA724F3 Q38641503-6FA3E4DD-5A51-457A-BA08-3E447CD27F90 Q47850608-0F1CB45C-AEA2-45B9-ABC7-5B838552BE85 Q59292055-2D388CF8-F085-4C67-A21E-50BD630C83CD

P2860

A prospective open-label study of aripiprazole in fragile X syndrome.

http://www.wikidata.org/entity/Q47293259

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

A prospective open-label study of aripiprazole in fragile X syndrome.

@en

A prospective open-label study of aripiprazole in fragile X syndrome.

@nl

type

label

A prospective open-label study of aripiprazole in fragile X syndrome.

@en

A prospective open-label study of aripiprazole in fragile X syndrome.

@nl

prefLabel

A prospective open-label study of aripiprazole in fragile X syndrome.

@en

A prospective open-label study of aripiprazole in fragile X syndrome.

@nl

P1433

Q47293259-16434CEB-8D89-4219-A2C1-0335E39CD474

P1476

Q47293259-AC99F2A1-3760-4C8E-9B39-A6078B6A0EF0

P2093

Q47293259-1DCE8D65-64AA-4B5C-88A9-67DCB5FCCD8A

Q47293259-4D86A288-C6E6-495F-A419-F2CD99A796C0

Q47293259-5178CC5A-0C18-4A72-AB88-B89FAD84B15F

Q47293259-566E3B1D-5EB8-45E1-B334-C5C69CA6C68F

Q47293259-8CC584DA-0C26-470E-9A32-89E1E8780B0C

Q47293259-F3E519C1-DF3A-4A39-BB5E-2912DBDB8086

P2860

Q47293259-01739B3A-2ED9-4050-B29D-7CA96DD2665E

Q47293259-1162C311-B6B4-4761-A432-266A5B12CA0B

Q47293259-11E1DDD4-1AC1-43A0-BD9A-86578CA1D1F0

Q47293259-16BE3E3C-F6A1-498B-BF80-DEDDC3039CC2

Q47293259-2D35BB5A-9967-484C-A60E-D18A26E4C828

Q47293259-32EE8185-D315-4AD0-91BB-4965B8C2F0C4

Q47293259-359B2E4D-1DA0-4F2A-ADB2-F0991B8E6235

Q47293259-39C23612-A197-47E6-A824-45BF54CFC85C

Q47293259-533CF06B-64DF-4BD7-A8AE-FB6253C6FB0A

Q47293259-6126D519-5C63-411D-94F2-225555CA13E7

P2888

Q47293259-C445F13C-7073-494C-954D-40F8C3F6FBC4

P304

Q47293259-2B68BB9A-67B0-4E24-856D-E88FA13F94F4

P31

Q47293259-A6F5E6C7-07CC-43B3-AC18-6175FFD0A372

P356

Q47293259-E2BCE838-7B72-4A0D-A84D-70D6CF7CDC5A

P433

Q47293259-13859079-2DAB-4DB0-AF82-30958D382455

P478

Q47293259-40E79F69-6BA7-4C89-864E-52C9A3D97399

P50

Q47293259-C55268A3-A4FC-4426-9B05-C47B4FA02246

P577

Q47293259-92FAB251-2F11-4889-A490-C4BAAF48C946

P698

Q47293259-EF59593F-3D53-4C4D-97B6-3D0970C76D99

P356

S00213-011-2194-7

P1433

Psychopharmacology

P1476

A prospective open-label study of aripiprazole in fragile X syndrome.

@en

P2093

Arlene Kohn

http://www.w3.org/2001/XMLSchema#string

Craig A Erickson

http://www.w3.org/2001/XMLSchema#string

David J Posey

http://www.w3.org/2001/XMLSchema#string

Jennifer E Mullett

http://www.w3.org/2001/XMLSchema#string

Kimberly A Stigler

http://www.w3.org/2001/XMLSchema#string

Logan K Wink

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the treatment of fragile X syndrome

Diagnosing autism: analyses of data from the Autism Diagnostic Interview.

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Risperidone in children with autism and serious behavioral problems.

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

Aripiprazole in autism spectrum disorders and fragile X syndrome.

Problem behavior in boys with fragile X syndrome.

Psychopharmacology in fragile X syndrome--present and future.

P2888

s00213-011-2194-7

P304

85-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-011-2194-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

216

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J McDougle

P577

2011-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21318565

http://www.w3.org/2001/XMLSchema#string